National Bank of Canada’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

National Bank of Canada’s Portfolio ZYNE Stock Details ZYNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-300	Closed	–	–	2947
2022 Q3	$0	Hold	300	–	–	﹤0.01%	2947
2022 Q2	$0	Hold	300	–	–	﹤0.01%	3052
2022 Q1	$1K	Hold	300	–	–	﹤0.01%	2822
2021 Q4	$1K	Buy	+300	New	+$1.11K	﹤0.01%	2786

Other funds holding ZYNE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EMG

ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PCM

Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

IEFM

IQ EQ Fund Management Dublin 2, Ireland $1.57B AUM 40.42% 1-Year Est. Return

National Bank of Canada's ZYNE Position: Q4 2022 in Review

National Bank of Canada sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q4 2022, closing a stake of 300 shares.

National Bank of Canada first reported a position in ZYNE in Q4 2021 and held it in 4 quarters. The position peaked at $1K in Q1 2022. 50 funds tracked by Wall St. Rank hold ZYNE as of Q4 2022.

National Bank of Canada reported no remaining Zynerba Pharmaceuticals, Inc position as of Q4 2022 after selling out during the quarter.
National Bank of Canada sold 300 Zynerba Pharmaceuticals, Inc shares in Q4 2022.
National Bank of Canada first reported a position in Zynerba Pharmaceuticals, Inc in Q4 2021 and held it in 4 quarters.
National Bank of Canada's Zynerba Pharmaceuticals, Inc position peaked at $1K in Q1 2022.
50 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q4 2022.

Based on National Bank of Canada's 13F filing for Q4 2022, filed 24 Jan 2023.